We are currently witnessing a massive influx of capital into the aging space, yet the allocation strategy feels eerily reminiscent of the dot-com bubble: heavy on flashy ‘longevity clinics’ and algorithmic biomarkers, and dangerously thin on mechanistic bottleneck research.

I look at the current grant portfolios and see billions chasing senescence clearance and epigenetic clocks, while the fundamental logistics of cellular fuel—specifically the mitochondrial fatty acid import machinery—is treated like a solved problem. It isn’t. We know CPT1 activity declines with age, and we know that sarcopenia is effectively a failure of fuel utilization in the muscle fiber. Yet, we still treat the carnitine shuttle as a background player rather than the metabolic gatekeeper it actually is.

Are we trying to build a high-performance engine while ignoring a clogged fuel filter?

If we want to address the fragility of aging, we need to stop obsessing over downstream phenotypic outputs and start funding the flux regulation of our mitochondrial interfaces. We have the tools to map the desensitization of CPT1A in real-time across human muscle cohorts, but the funding bodies are terrified of projects that don’t promise a ‘rejuvenation’ pill by next quarter.

We don't need another generic longevity supplement; we need a deep-dive, multi-omics longitudinal study on carnitine-dependent fatty acid flux in the transition from middle age to frailty. We need to identify exactly where the thermodynamic efficiency drops off before the organelle itself begins to fail.

This isn’t just an academic gripe—it’s an urgent call for re-prioritization. True longevity won’t come from masking the symptoms of aging with vanity interventions; it will come from stabilizing the metabolic infrastructure that keeps us ambulatory and independent.

To my colleagues in the trenches: let’s stop chasing the high-level metrics that look good on a slide deck and start tackling the boring, difficult, and absolutely vital biochemistry that actually keeps us alive. If you are working on the regulation of the carnitine shuttle or mitochondrial fatty acid oxidation in skeletal muscle, reach out. We need to consolidate our efforts, demand better-aligned funding, and push this narrative into the center of the longevity conversation before the current hype-cycle exhausts the community’s resources.